RESTON, Va.--SNM is bringing a molecular imaging presence to the 9th World Congress of Nuclear Medicine and Biology that is being held Oct. 22-27 in Seoul, Korea. Members of the society, an international scientific and professional organization of more than 16,000 physician, technologist and scientist members, have organized a molecular imaging categorical seminar on Oct. 22, and SNM and SNMTS members are assisting in developing and presenting other sessions.

"This categorical seminar directly reflects SNM's core mission `to advance health care by advancing molecular imaging and therapy,'" said SNM President-Elect Sandy McEwan, who will be presenting several sessions at the congress. "SNM has traditionally represented all professionals involved in the practice of nuclear medicine. It is the society within which molecular imaging originated. SNM now also supports the new field of molecular imaging and those scientists, clinicians and technologists involved in this emerging medical imaging contribution to improving patient care," added the director of oncologic imaging at Cross Cancer Institute in Edmonton, Alberta, Canada.

"SNM is determined to advance molecular imaging, " explained Mathew L. Thakur, SNM 2004-05 president and seminar organizer. "This categorical seminar is designed to share with the world nuclear medicine community the recent advances in molecular imaging made by some of the experts in the field. The seminar encompasses topics in basic, translational and clinical research and promises to be educational to everyone," noted the a professor of radiology and radiation oncology and the director of radiopharmaceutical and nuclear medicine research at Thomas Jefferson University Medical College in Philadelphia, Pa.

Participants in SNM's molecular imaging categorical seminar and their topics include McEwan, "Imaging of Cell Death and Signaling Networks"; Thakur, "Genomic and Proteomic Approaches to MI of Cancer"; SNM 2005-06 President Peter S. Conti, University Southern California, Los Angeles, "Translational MI With PET Tracers"; Xiaoyuan Chen, Stanford University, Stanford, Calif., "The Evolving Role of Nanotechnology in MI of Cancer"; Juri Gelovani, University of Texas M.D. Anderson Cancer Center, Houston, Texas, "A Paradigm for the Development and Application of Optical-Nuclear, Dual-Labeled Imaging Agents"; Henry VanBrocklin, Lawrence Berkeley Labs, Berkeley, Calif., "Neuroimaging of Alzheimer's Disease"; and Michael Welch, Mallinckrodt Institute of Radiology, St. Louis, Mo., "Targeted Imaging and Drug Development."

More Industry Headlines